Nxera Pharma Co Ltd (SOLTF) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you very much for joining us today. I'm Nobura, CFO of Nexara Pharma Co Ltd. Today, we have Chris Cargill, COO of COO and President of Nexera Japan, Toshihiro Maeda, and Patrick Foerch, President of CSO and Nexera UK. We have the same ability, so if you click on the language selection icon of Zoom and choose between Japanese or English, you will be able to listen to the translation sound. If you keep it off, you will be able to hear the original sound of the speaker. Today, we are going to explain the information according to the information in the first half of the video and answer questions in the second half of the video. The information is shared on the screen, but it is also posted on the homepage. If you have access to the information, please enter it from the investors on the left side of the homepage and proceed to the IR library. If you have any questions, please feel free to ask them in the Q&A section below. Please feel free to post your questions in the Q&A section below. Let's move on to the explanation. First, Chris will explain the business highlights, then I will explain the summary of the settlement, the update of the APAC business in Japan from Maeda, and the progress of research and development from Patrik. Finally, I will go back to Chris and explain the future prospects. Please take a look at the five pages of the material. Chris, thank you. Thank you very much Nomura-san. And just a quick disclaimer, please note that today's presentation does contain forward-looking statements and the actual results may differ from them. The details are here on slide number two. So welcome and thank you for joining us for NextEra Pharma's results for the first half of financial year 2026. I am Chris Cargill, President and Chief Executive Officer of NextEra...